Drug Type Biosimilar, Enzyme |
Synonyms P-046 |
Target |
Action stimulants |
Mechanism IDUA stimulants(Alpha-L-iduronidase stimulants), α-L-iduronidase replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 3 |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Mucopolysaccharidosis I | Phase 3 | Iran | 10 Sep 2022 |
Phase 3 | 12 | (Crossover Phase 2) | sokddgbmow(wslljhzlkc) = xrrmmxdshs kjgggssgqt (ccatrdemkm, 177.13) | Positive | 19 Aug 2025 | ||
Reference Laronidase (Crossover Phase 1) | sokddgbmow(wslljhzlkc) = kcnzcvtrzi kjgggssgqt (ccatrdemkm, 111.55) |






